Is COGT a good stock to buy?
We came across a bullish thesis on Cogent Biosciences, Inc. on X.com by @seedy19tron
In this article, we will summarize the bulls’ thesis on COGT. Cogent Biosciences, Inc.’s share was trading at $34.81 as of June 1st. Likoper/ Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, primarily systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST).
Its lead asset bezuclastinib is a highly selective type I KIT inhibitor targeting KIT D816V, positioning it as a differentiated therapy in mast-cell driven oncology. Beyond its lead program, the company is advancing a broader pipeline including a pan-KRAS(ON) inhibitor CGT1815, a JAK2 inhibitor CGT1145, and FGFR2/3 assets, expanding its optionality across solid tumors and hematologic malignancies. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential Investors see peak sales potential exceeding 3 billion dollars for bezuclastinib alone, which underpins the market’s mispricing argument. In second-line GIST, bezuclastinib plus Sutent demonstrated a median progression-free survival of 16.5 months versus 9.2 months for standard of care, supporting meaningful efficacy differentiation.